AUTHORS
ABSTRACT
We appreciate the opportunity to justify our assumptions about the efficacy of typhoid conjugate vaccines (TCVs) in response to John Bosco Kalule’s Correspondence. In the transmission-dynamic model that we used to evaluate the cost-effectiveness of TCV delivery strategies across Gavi, the Vaccine Alliance-eligible countries, vaccine efficacy was characterised by two parameters: the initial vaccine efficacy (the so-called vaccine take) and the rate of waning of vaccine-induced immunity.
Click here to read the article, published in The Lancet.